# Study to Assess the Clinical Activity of a Sequential Dose of REGN846 on Refractory Pruritus in Patients With Atopic Dermatitis

> **NCT01605708** · PHASE1,PHASE2 · TERMINATED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 19 (actual)

## Conditions studied

- Pruritus
- Atopic Dermatitis

## Interventions

- **DRUG:** REGN846

## Key facts

- **NCT ID:** NCT01605708
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-06
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2013-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01605708

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01605708, "Study to Assess the Clinical Activity of a Sequential Dose of REGN846 on Refractory Pruritus in Patients With Atopic Dermatitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01605708. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*